Biology of vascular endothelial growth factors

Roy, Himadri; Bhardwaj, Shalini; Ylä‐Herttuala, Seppo

doi:10.1016/j.febslet.2006.03.087

Cited by 454 publications

(423 citation statements)

References 70 publications

Supporting

Mentioning

396

Contrasting

Unclassified

Order By: Relevance

“…It can also form a heterodimer with PlGF, and this stimulates angiogenesis via the VEGFR-1/VEGFR-2 heterodimer (Autiero et al, 2003;Roy et al, 2006); this is consistent with our finding that VEGF/PlGF was present at substantially higher levels in AML patients than in the healthy controls. Loges et al (2005) reported that the AML patients and healthy donors …”

Section: Discussionsupporting

confidence: 91%

Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia

Tien

et al. 2007

Br J Cancer

View full text Add to dashboard Cite

Bone marrow (BM) neoangiogenesis plays an important role in acute myelogenous leukaemia (AML), and depends on the interplay of members of the vascular endothelial growth factor (VEGF) and angiopoietin (Ang) families. We determined the marrow levels of seven molecules associated with angiogenesis in 52 AML patients before chemotherapy and 20 healthy controls: VEGF-A, VEGF/PlGF, VEGF-C, VEGF-D, Ang-1, Ang-2, and Tie-2. All the molecules were quantified using enzyme-linked immunosorbent assay (ELISA). Comparing to normal controls, the marrow levels of VEGF/PlGF, Ang-2, and Tie-2 were significantly higher, and those of VEGF-C and Ang-1 were significantly lower in the AML patients ( P <0.001). A total of 31 patients were further subjected to survival analysis. Patients with lower Tie-2 (<26 ng ml −1 ) and Ang-2 levels (<4500 pg ml −1 ) displayed a survival advantage ( P =0.037 and 0.042, respectively), same as patients with higher VEGF/PlGF (⩾1 pg ml −1 ) and VEGF-D levels (⩾350 pg ml −1 ) ( P =0.020 and 0.016, respectively). An angio-index ((Ang-2 × Tie-2)/(VEGF/PlGF × VEGF-D)) was established and multivariate Cox regression analysis revealed that patients with higher angio-index values (⩾50) displayed poor prognosis (hazard ratio 5.91, 95% confidence interval 1.99–17.56; P =0.001). The angio-index is closely associated with the clinical outcome of AML patients and may be valuable in disease prognosis.

show abstract

Section: Discussionsupporting

confidence: 91%

Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia

Tien

et al. 2007

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Angiogenesis is an important step in the development of cancer and is necessary for primary tumor growth, invasiveness, and metastasis (Ferrara et al, 2003) the most potent endothelial cell mitogens and plays and important role in angiogenesis (Belinsky et al, 2005;Roy et al, 2006). VEGF is a major mediator of breast cancer angiogenesis.…”

Section: Introductionmentioning

confidence: 99%

Vascular Endothelial Growth Factor (VEGF) Gene Polymorphisms and Breast Cancer Risk in a Chinese Population

Luo¹,

Chen²,

He³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Systemic or topical drugs acting in the wound repair and regeneration processes, have been proven to be promising and useful agents for the treatment of chronic venous ulcers (5). Wound repair depends both on neoangiogenesis and the activation of a local immune response, and on the presence of growth factors including epidermal growth factor (EGF), transforming growth factor ß (TGF-ß), and basic fibroblast growth factor (bFGF) (6)(7)(8)(9). It has also been demonstrated that the local injection of granulocyte-macrophage colony stimulating factor (GM-CSF) is able to promote and accelerate the wound repair of chronic venous leg ulcers by increasing several cellular functions such as the migration of epithelial cells, local recruitment of inflammatory cells and the proliferation of keratinocytes (10,11).…”

Section: Introductionmentioning

confidence: 99%

Topical treatment of chronic venous ulcers with sucralfate: A placebo controlled randomized study

Tumino¹,

Masuelli²,

Bei³

et al. 2008

Int J Mol Med

View full text Add to dashboard Cite

Abstract. Venous leg ulcers are an important medical issue due to their high incidence in the elderly and the lack of a standard curative approach. Apart from surgical therapy, different medical treatments to effect ulcer wound repair and regeneration are currently being investigated. Sucralfate is a cytoprotective agent employed to prevent or treat several gastrointestinal diseases such as gastroesophageal reflux, gastritis, peptic ulcer, stress ulcer and dyspepsia. In this study we evaluated the efficacy, safety and tolerability of topical sucralfate (SUC-LIS 95) on the healing of chronic venous leg ulcers in 50 patients by a double-blind, placebo-controlled, randomized study. Our results indicated that the daily application of SUC-LIS 95 to non-infected post-phlebitis/vascular ulcers, for a median period of 42.0 days, led to complete healing in 95.6% of patients, against only 10.9% of cases with a matched placebo. A significant improvement was obtained in the SUC-LIS 95-treated patient group with regard to local tissue inflammation as well as pain and burning, and consequently, in ulcer size and the evolution of granulation tissue. Our findings were corroborated for selected patients by the morphological analysis of biopsies obtained before and after treatment. Using ultrastructural analysis we demonstrated that the topical use of SUC-LIS 95 was able to affect neoangiogenesis, increase wound contraction, promote re-epithelialization of the wound area and diminish the inflammatory reaction. Overall, our results indicated that patients with chronic venous ulcers show improvement after the use of topical sucralfate.

show abstract

Biology of vascular endothelial growth factors

Abstract: Angiogenesis is the process by which new blood vessels are formed from existing vessels. The vascular endothelial growth factors (VEGFs) are considered as key molecules in the process of angiogenesis. The VEGF family currently includes VEGF-

Cited by 454 publications

References 70 publications

Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia

Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia

Vascular Endothelial Growth Factor (VEGF) Gene Polymorphisms and Breast Cancer Risk in a Chinese Population

Topical treatment of chronic venous ulcers with sucralfate: A placebo controlled randomized study

Contact Info

Product

Resources

About